<DOC>
	<DOCNO>NCT00056095</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplant may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : This phase II trial study well allogeneic stem cell transplant work treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplant Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine 18-month survival rate patient metastatic renal cell carcinoma treat allogeneic stem cell transplantation . - Determine objective rate response patient treat regimen . - Determine post-transplant immunological reaction recuperation patient treat regimen . - Determine antitumoral activity regimen patient . OUTLINE : This non-randomized , multicenter study . Patients assign 1 2 treatment group base availability compatible family member stem cell transplantation . - Group I : Patients compatible family donor receive condition chemotherapy comprise cyclophosphamide IV 2 hour day -7 -6 fludarabine IV daily day -5 -1 . Patients undergo filgrastim ( G-CSF ) -mobilized allogeneic stem cell transplantation day 0 . Patients also receive immunosuppression therapy cyclosporine begin day -2 . Patients persistent progressive disease , mixed chimerism , evidence grade 2 great graft-vs-host disease , immunosuppression therapy 1-2 week receive donor lymphocyte infusion day 7 21 . - Group II : Patients without compatible family donor receive treatment ( immunotherapy , vaccination therapy , chemotherapy ) discretion treat physician . Patients follow every 3 month 5 year . PROJECTED ACCRUAL : A total 170 patient ( 60 patient group I 110 patient group II ) accrue study within 3 year .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic renal cell carcinoma No sarcomatoid , pure papillary , Bellini renal cell cancer Measurable and/or evaluable disease Disease progression least 1 immunotherapy regimen metastatic disease Localized metastases allow provide follow true : At least 3 month since prior treatment metastasis Not consider likely influence outcome transplantation No brain metastasis unless treat surgically radiologically MRI normal Sufficiently healthy , HLAcompatible family member must available donor patient undergoing stem cell transplantation PATIENT CHARACTERISTICS : Age 18 65 Performance status ECOG 01 Life expectancy More 6 month Hematopoietic Platelet count least 100,000/mm^3 Hepatic Transaminases le 1.5 time upper limit normal ( ULN ) * Bilirubin le 1.5 time ULN* NOTE : *Unless due Gilbert 's disease Renal No renal insufficiency Calcium le 10.4 mg/dL Creatinine clearance great 50 mL/min Cardiovascular Ejection fraction great 50 % Pulmonary No DLCO would preclude fludarabine busulfan therapy Other Not pregnant nursing Fertile patient must use effective contraception No physical obstacle receive study treatment No know autoimmune disease No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No uncontrolled bacterial , viral , fungal infection No prior concurrent psychiatric disease HIV negative HTLV1 negative PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy No tolerance fludarabine busulfan Endocrine therapy No concurrent corticosteroid Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>